Cystic Fibrosis Epidemiology

Cystic fibrosis is an autosomal recessive inherited disorder affecting salt transport in and out of cells. The resulting imbalance of fluids and salts causes the production of a thick, sticky mucus and other abnormalities throughout the body. The lungs are the principal organ affected, but cystic fibrosis also affects the pancreas, gastrointestinal system, reproductive system, and many other organs of the body.

Prevalence

Cystic fibrosis affects more than 30,000 people in the U.S. and is one of the most common genetic diseases of Caucasian people. About a thousand new cases are diagnosed annually--typically within one year of birth. Lifespans have increased over the past few decades, and currently the average survival is about 40 years.

Cystic fibrosis. Image Credit: Alila Medical Media / Shutterstock
Cystic fibrosis. Image Credit: Alila Medical Media / Shutterstock

Genetics

Cystic fibrosis is caused by any of a range of mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. A child inherits one CFTR allele from each parent. Disease is present when both alleles have mutations. A person who has a mutation on just one allele is a carrier. More than 70 percent of cases of cystic fibrosis are caused by the f508del mutation, but over a thousand other mutations have been identified.

Different Populations

The prevalence of cystic fibrosis varies quite a bit between different racial and ethnic groups. The birth prevalence among those Caucasian people in the U.S. who have North European heritage is 1:2500. This is 13 times higher than Asian-American populations, where the prevalence is 1:32 000.

Worldwide, the incidence of cystic fibrosis is as high as 1:377 in parts of England and as low as 1:90 000 among Asian people in Hawaii. In Europe, the rate of cystic fibrosis is between 1:2000 and 1:3000 births. In southern Africa, the carrier frequency is 1 in 42, with a calculated incidence of 1 in 7056 births. The incidence in Latin America ranges from 1:3900 to 1:8500. Estimates for the Middle East are between 1:2560 and 1:15,876.

Cystic fibrosis is rare among Asians. In India, the prevalence is estimated at around 1:40 000 to 1:100 000 births. In Japan, the estimated incidence is 1:100 000 to 1:350 000.

Under-Diagnosis of Cystic Fibrosis

In some parts of the world, cystic fibrosis is under-diagnosed, and the true prevalence of the disease is not known. This includes Latin America, Africa, and India. Lack of knowledge about the disease, poor access to health care, confounding diagnoses, a high level of infant mortality in general, and low life expectancy all contribute to the under-diagnosis of the disease.

Increased Adult Population

Outcomes and survival rates for cystic fibrosis have improved drastically over the past fifty years. Once an exclusively pediatric illness due to early mortality, cystic fibrosis victims are now surviving more and more commonly into adult life. The median age of patients with cystic fibrosis in the U.S. is 17.9 years, and some patients are as old as 85 years. The proportion of adult patients has increased from 29.2 percent in 1986 to 49.7 percent in 2013.

References

  1. Arch Intern Med, Genetic testing for cystic fibrosis. National Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis, https://www.ncbi.nlm.nih.gov/pubmed/10421275
  2. The Molecular Genetic Epidemiology of Cystic Fibrosis, https://www.who.int/
  3. Clin Chest Med., Epidemiology of Cystic Fibrosis, https://www.ncbi.nlm.nih.gov/pubmed/26857763
  4. Clin Chest Med., Cystic fibrosis: a review of epidemiology and pathobiology, https://www.ncbi.nlm.nih.gov/pubmed/17467547
  5. CFTR Science, Epidemiology: The mutational diversity of cystic fibrosis, https://www.cftrscience.ca/

Further Reading

Last Updated: Dec 29, 2022

Dr. Catherine Shaffer

Written by

Dr. Catherine Shaffer

Catherine Shaffer is a freelance science and health writer from Michigan. She has written for a wide variety of trade and consumer publications on life sciences topics, particularly in the area of drug discovery and development. She holds a Ph.D. in Biological Chemistry and began her career as a laboratory researcher before transitioning to science writing. She also writes and publishes fiction, and in her free time enjoys yoga, biking, and taking care of her pets.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Shaffer, Catherine. (2022, December 29). Cystic Fibrosis Epidemiology. News-Medical. Retrieved on December 22, 2024 from https://www.news-medical.net/health/Cystic-Fibrosis-Epidemiology.aspx.

  • MLA

    Shaffer, Catherine. "Cystic Fibrosis Epidemiology". News-Medical. 22 December 2024. <https://www.news-medical.net/health/Cystic-Fibrosis-Epidemiology.aspx>.

  • Chicago

    Shaffer, Catherine. "Cystic Fibrosis Epidemiology". News-Medical. https://www.news-medical.net/health/Cystic-Fibrosis-Epidemiology.aspx. (accessed December 22, 2024).

  • Harvard

    Shaffer, Catherine. 2022. Cystic Fibrosis Epidemiology. News-Medical, viewed 22 December 2024, https://www.news-medical.net/health/Cystic-Fibrosis-Epidemiology.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Enterprise Therapeutics publishes on medicinal chemistry of ETD001, a novel inhaled ENaC blocker for treatment of cystic fibrosis